Table 2.
Summary results for SNP genotyping analysis in South African men.
| rs number | Cytoband | In/nearest gene‡ |
Effect allele; frequency (control | case); per effect allele OR (95% CI)a; p value (adjusted for age) |
||
|---|---|---|---|---|---|
| Mixed Ancestry | White | Combinedb | |||
| rs9364554 | 6q25 | SLC22A3 | T; (0.13 | 0.11); 0.236 |
T; (0.20 | 0.21); 0.493 |
T; (0.17 | 0.15); 0.737 |
|
| |||||
| rs10486567 | 7p15 | JAZF1 | G; (0.17 | 0.22); 0.098 |
G; (0.15 | 0.19); 1.89 (1.11–3.28); 0.019 |
G; (0.16 | 0.21); 1.42 (1.08–1.85); 0.011 |
|
| |||||
| rs6465657 | 7q21 | LMTK2 | T; (0.18 | 0.14); 0.56 (0.36–0.87); 0.010 |
T; (0.18 | 0.23); 0.226 |
T; (0.18 | 0.17); 0.455 |
|
| |||||
| rs7008482 | 8q24 | NSMCE2 | T; (0.44 | 0.31); 0.41 (0.26–0.62); 2.45 × 10−5 |
G; (0.42 | 0.42); 0.877 |
T; (0.51 | 0.60); 0.48 (0.34–0.68); 3.87 × 10−5 |
|
| |||||
| rs6983561 | 8q24 | PRNCR1 | C; (0.16 | 0.18); 0.335 |
C; (0.06 | 0.10); 0.067 |
C; (0.11 | 0.15); 0.078 |
|
| |||||
| rs6983267 | 8q24 | POU5F1P1 | T; (0.41 | 0.26); 0.35 (0.23–0.53); 4.48 × 10−7 |
T; (0.39 | 0.37); 0.774 |
T; (0.40 | 0.30); 0.53 (0.39–0.73); 8.05 × 10−5 |
|
| |||||
| rs4242382 | 8q24 | POU5F1P1 | A; (0.24 | 0.19); 0.59 (0.39–0.89); 0.013 |
A; (0.20 | 0.19); 0.768 |
A; (0.22 | 0.19); 0.11 |
|
| |||||
| rs10993994 | 10q11 | MSMB | T; (0.27 | 0.37); 1.56 (1.56–6.08); 1.40 × 10−3 |
T; (0.12 | 0.33); 3.49 (2.28–5.54); 1.56 × 10−9 |
T; (0.20 | 0.35); 2.09 (1.64–2.68); 3.03 × 10−9 |
|
| |||||
| rs4962416 | 10q26 | CTBP2 | C; (0.49 | 0.46); 0.61 (0.36–0.97); 0.035 |
T; (0.43 | 0.47); 0.305 |
T; (0.48 | 0.46); 0.338 |
|
| |||||
| rs7931342 | 11q13 | MYEOV | T; (0.44 | 0.38); 0.064 |
T; (0.48 | 0.48); 0.664 |
T; (0.46 | 0.41); 0.091 |
|
| |||||
| rs4430796 | 17q12 | HNF1B | A; (0.44 | 0.39); 0.433 |
A; (0.48 | 0.44); 0.48 (0.26–0.84); 0.010 |
A; (0.46 | 0.45); 0.424 |
|
| |||||
| rs1859962 | 17q24 | CASC17 | G; (0.28 | 0.28); 0.757 |
G; (0.29 | 0.36); 1.42 (1.01–2.01); 0.044 |
G; (0.28 | 0.30); 0.302 |
|
| |||||
| rs2735839 | 19q13 | KLK3 | A; (0.31 | 0.36); 0.149 |
A; (0.36 | 0.34); 0.734 |
A; (0.33 | 0.35); 0.377 |
Only p < 1.47 × 10−3 (Bonferroni correction) indicated in bold text was considered statistically significant.
aOR (95% CI) only shown for SNPs where p < 0.05.
bAdjusted for age and ethnicity.
‡Genes indicated have been shown to be involved in prostate tumour onset or progression or to have altered expression in prostate tumours [34–41], except NSMCE2, shown to alter growth rates of breast cancer cells [42], MYEOV, shown to be overamplified in breast and oesophageal carcinomas [43], and CASC17, a long nonprotein coding RNA gene.